CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.…
CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
CorMedix (NASDAQ: CRMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 191 employees.
The shares were at 5.270 USD on 20 November 2026, down 51.1% over 52 weeks. Its 52-week range is 4.465 USD to 13.02 USD: the price is 59.5% below the high and 18.0% above the low.
At a market capitalisation of 419.16M USD, it trades at 8.2 times trailing earnings and 15.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 75% for CRMD.
CorMedix reports return on equity of 40.2%, an operating margin of 41.0% and revenue down 47.7% year over year.
It holds more cash than debt, a net cash position of 207.69M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 13.80 USD is 161.9% above the current price. The next earnings report is expected on 11 March 2027.